- The European Medicines Agency has accepted for review Pfizer Inc's (NYSE: PFE) marketing application seeking approval for the 20-valent pneumococcal conjugate vaccine (20vPnC).
- The vaccine candidate is for preventing invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults ages 18 years and older.
- The U.S. marketing application for 20vPnC is also currently under review, with the agency's goal date in June 2021.
- In June 2020, Pfizer initiated two Phase 3 trials for 20vPnC evaluating the safety and efficacy of the investigational vaccine in infants.
- Price Action: PFE is down 0.09% at $33.79 in premarket trading on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
